Manager TitleAgeSince
Chief Operating Officer - 13/11/2022
Director TitleAgeSince
Director/Board Member 61 15/08/2005
Chairman 67 18/09/2014
Director/Board Member 55 04/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-4.12% - - 1.28M
+0.47%+2.27%+50.78%+69.72% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+1.14%+1.50%-16.39%-14.39% 23.38B
-0.74%-2.73%-1.21%+369.56% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%-2.30%+27.27%-33.01% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-0.90%+1.53%+51.11%+183.21% 14.2B
Average -0.28%-0.56%+40.40%+164.17% 26.35B
Weighted average by Cap. +0.45%-0.20%+37.43%+129.10%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
-